IMPT-514 Clin0 Lupus Nehpritis; undisclosed RD gastric cancer
ImmPACT Bio is a preclinical-stage biotechnology company developing logic-gate-based CAR T platforms that address key challenges for current cell therapies in oncology. The company's technologies are designed to prevent antigen escape, to overcome the immunosuppressive tumor environment, and to cure autoimmune disease. ImmPACT Bio's logic-gate-based CAR T platforms are designed to be more specific and effective than traditional CAR T therapies. Traditional CAR T therapies target a single antigen on cancer cells. This can lead to antigen escape, where cancer cells lose the antigen that the CAR T cells are targeting. ImmPACT Bio's logic-gate-based CAR T platforms target multiple antigens on cancer cells, which reduces the risk of antigen escape.